
ZNTL
Healthcare · Biotechnology · $167.1M market cap
$1.70+0.02 (+1.2%)Nov 13, 4:16 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -5.9% over 90 days · 30-day revisions 2 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 25, 2027 · upcoming | After the close | -0.51 | — | — |
| Nov 9, 2026 | After the close | -0.58 | -0.34 | +41.4% |
| Aug 6, 2026 | After the close | -0.45 | -0.59 | -31.1% |
| May 13, 2026 | Time not confirmed | -0.47 | -0.50 | -7.4% |
| Mar 26, 2026 | After the close | -0.61 | -0.49 | +19.7% |
| Nov 10, 2025 | After the close | -0.48 | -0.37 | +22.9% |
| Aug 6, 2025 | After the close | -0.52 | -0.37 | +28.8% |
| May 14, 2025 | After the close | -0.61 | -0.67 | -9.8% |
| Feb 25, 2025 | Before the open | -0.68 | -0.61 | +10.0% |
| Nov 12, 2024 | After the close | -0.87 | -0.56 | +35.6% |
| Aug 9, 2024 | Before the open | -0.83 | -1.24 | -49.4% |
| May 7, 2024 | Before the open | -0.74 | 0.14 | +118.9% |
| Feb 27, 2024 | Before the open | -0.92 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in…
| -0.93 |
| -1.1% |
| Nov 6, 2023 | Before the open | -0.94 | -0.79 | +16.0% |
| Aug 9, 2023 | Before the open | -1.02 | -1.85 | -81.4% |
| May 10, 2023 | Before the open | -1.03 | -1.07 | -3.9% |
| Mar 1, 2023 | Before the open | -1.06 | -0.92 | +13.2% |
| Nov 9, 2022 | Before the open | -1.19 | -0.96 | +19.3% |
| Aug 9, 2022 | After the close | -1.20 | -1.34 | -11.7% |
| May 5, 2022 | Before the open | -1.20 | -1.31 | -9.2% |
| Feb 24, 2022 | Before the open | -1.49 | -1.11 | +25.5% |
| Nov 10, 2021 | Before the open | -1.25 | -0.09 | +92.8% |
| Aug 12, 2021 | Before the open | -1.16 | -1.34 | -15.5% |
| May 17, 2021 | Before the open | -0.91 | -1.24 | -36.3% |
| Mar 25, 2021 | Before the open | -0.95 | -1.01 | -6.3% |
| Nov 9, 2020 | Before the open | -0.76 | -0.91 | -19.7% |
| Aug 13, 2020 | Before the open | -0.49 | -0.78 | -59.2% |
| May 15, 2020 | Before the open | -0.47 | -2.88 | -512.8% |